top of page

People in Liverpool Return For Pioneering NHS Cancer Study

Hundreds Of Volunteers Across Liverpool Are Returning To Help The NHS Research A Pioneering Test To Detect Cancer Earlier

The test works by analysing chemical patterns in fragments of DNA that are shed from tumours into the bloodstream. If early trial results are promising, the NHS may decide to pilot the delivery of the test to a further one million people (Credit: NHS/Supplied/Image was provided to The Liverpudlian to share, courtesy of the Publicist on behalf of their client. We make no claim to this content).
The test works by analysing chemical patterns in fragments of DNA that are shed from tumours into the bloodstream. If early trial results are promising, the NHS may decide to pilot the delivery of the test to a further one million people (Credit: NHS/Supplied/Image was provided to The Liverpudlian to share, courtesy of the Publicist on behalf of their client. We make no claim to this content).

They will have the last of three blood samples taken for the NHS-Galleri trial, which 22,000 people in Merseyside and Cheshire are taking part in. The study is investigating if the multi-cancer blood screening test can help to spot cancer before symptoms appear.


Participants in Liverpool are now receiving an invitation to have a final blood sample taken at a mobile clinic stationed at Aintree Shopping Park on Ormskirk Road in Aintree, from the 9th of January to the 5th of February 2024.

'We are delighted to be welcoming back volunteers from Liverpool for their last trial appointment and we are truly grateful for their ongoing participation.' - Dr Chris Warburton, Medical Director at Cheshire and Merseyside Cancer Alliance.

Dr Chris Warburton, Medical Director at Cheshire and Merseyside Cancer Alliance, said: 'We are delighted to be welcoming back volunteers from Liverpool for their last trial appointment and we are truly grateful for their ongoing participation. Even if you missed your appointment last year, your involvement this year will still help with this research.'


Dr Warburton added: 'This trial – launched nationally in Cheshire and Merseyside in 2021 – continues to put the NHS at the forefront of ground-breaking research and technology. If this trial is a success, the Galleri blood test could play a major part in achieving the NHS Long Term Plan ambition to diagnose three-quarters of cancers at an early stage when they are easier to treat.'

The test works by analysing chemical patterns in fragments of DNA that are shed from tumours into the bloodstream. If early trial results are promising, the NHS may decide to pilot the delivery of the test to a further one million people (Credit: NHS/Supplied/Image was provided to The Liverpudlian to share, courtesy of the Publicist on behalf of their client. We make no claim to this content).


Professor Charles Swanton, Co-Chief Investigator for the NHS-Galleri trial, said: 'The information gathered from these last appointments is important to support trial results. Testing samples taken about 12 months apart will help researchers to understand how regularly people might need to be tested with the Galleri blood test in the future. We thank all volunteers for supporting the trial.'


Early research has shown that the Galleri test could help to detect cancers that are typically difficult to identify early – such as head and neck, bowel, lung, pancreatic, and throat cancers. The test works by analysing chemical patterns in fragments of DNA that are shed from tumours into the bloodstream. If early trial results are promising, the NHS may decide to pilot the delivery of the test to a further one million people.

.Testing samples taken about 12 months apart will help researchers to understand how regularly people might need to be tested with the Galleri blood test in the future.' - Professor Charles Swanton, Co-Chief Investigator for the NHS-Galleri trial.

The NHS-Galleri trial is being run by The Cancer Research UK and King’s College London Cancer Prevention Trials Unit in partnership with the NHS and healthcare company, GRAIL, which has developed the Galleri test. The trial is operating with the support of eight NHS cancer alliances across England, including Cheshire and Merseyside, and it is rolling out across our region until June next year.


For more information on the trial, see their website.

Komentarze


bottom of page